Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2020 1
2021 2
2022 8
2023 7
2024 7
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Phototherapy for atopic eczema.
Musters AH, Mashayekhi S, Harvey J, Axon E, Lax SJ, Flohr C, Drucker AM, Gerbens L, Ferguson J, Ibbotson S, Dawe RS, Garritsen F, Brouwer M, Limpens J, Prescott LE, Boyle RJ, Spuls PI. Musters AH, et al. Cochrane Database Syst Rev. 2021 Oct 28;10(10):CD013870. doi: 10.1002/14651858.CD013870.pub2. Cochrane Database Syst Rev. 2021. PMID: 34709669 Free PMC article.
Real-world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: Results from the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
Musters AH, van Lookeren FL, van der Gang LF, Middelkamp-Hup MA, Bosma AL, Jessurun NT, Lapeere H, Nguyen AL, Ouwerkerk W, de Schepper S, Gerbens LAA, Spuls PI. Musters AH, et al. J Eur Acad Dermatol Venereol. 2024 Mar;38(3):530-542. doi: 10.1111/jdv.19643. Epub 2023 Nov 29. J Eur Acad Dermatol Venereol. 2024. PMID: 38031478
From the Cochrane Library: Phototherapy for atopic eczema.
O'Connell KA, Kim LS, Szeto MD, Sivesind T, Dellavalle RP, Musters AH, Spuls PI. O'Connell KA, et al. J Am Acad Dermatol. 2022 Jul;87(1):e23-e26. doi: 10.1016/j.jaad.2022.03.010. Epub 2022 Mar 8. J Am Acad Dermatol. 2022. PMID: 35276284 No abstract available.
Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT) registry taskforce.
Musters AH, Gerbens LAA, van der Gang L, Middelkamp-Hup MA, Ouwerkerk W, Hijnen DJ, Haufe E, Heinrich L, Werfel T, Weidinger S, Schmitt J, Svedbom A, Johansson EK, Bradley M, von Kobyletzki LB, Vittrup I, Ruge IF, Thyssen JP, Vestergaard C, Carrascosa JM, de Vega M, García-Doval I, Chiricozzi A, Stingeni L, Calzavara-Pinton P, Ardern-Jones MR, Reynolds NJ, Flohr C, Spuls PI; A‐STAR, AtopyReg, BIOBADATOP, SCRATCH, SwedAD, TREATgermany and TREAT NL/BE registry teams. Musters AH, et al. J Eur Acad Dermatol Venereol. 2025 Aug 20. doi: 10.1111/jdv.20876. Online ahead of print. J Eur Acad Dermatol Venereol. 2025. PMID: 40832875
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations.
van Dam KPJ, Wieske L, Stalman EW, Kummer LYL, Roosen J, van Kempen ZLE, Killestein J, Volkers AG, Boekel L, Wolbink GJ, van der Kooi AJ, Raaphorst J, Löwenberg M, Takkenberg RB, D'Haens GRAM, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Hilhorst ML, Vegting Y, Bemelman FJ, Voskuyl AE, Broens B, Sanchez AP, van Els CACM, de Wit J, Rutgers A, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart RCF, Teng YKO, van Paassen P, Busch MH, Jallah PBP, Brusse E, van Doorn PA, Baars AE, Hijnen DJ, Schreurs CRG, van der Pol WL, Goedee HS, Steenhuis M, Keijzer S, Keijser JBD, Cristianawati O, Rispens T, Brinke AT, Verstegen NJM, Marieke van Ham S, Tas SW, Kuijpers TW, Eftimov F; T2B! Immunity against SARS-CoV-2 study group. van Dam KPJ, et al. J Autoimmun. 2023 Feb;135:102984. doi: 10.1016/j.jaut.2022.102984. Epub 2023 Jan 2. J Autoimmun. 2023. PMID: 36621174 Free PMC article.
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases.
Stalman EW, Wieske L, van Dam KPJ, Kummer LY, van Kempen ZLE, Killestein J, Volkers AG, Tas SW, Boekel L, Wolbink GJ, Van der Kooi AJ, Raaphorst J, Löwenberg M, Takkenberg RB, D'Haens GRAM, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Hilhorst ML, Vegting Y, Bemelman FJ, Voskuyl AE, Broens B, Parra Sanchez A, van Els CACM, Wit J, Rutgers A, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart CF, Teng OYK, van Paassen P, Busch MH, Jallah PBP, Brusse E, van Doorn PA, Baars AE, Hijnen DJ, Schreurs CRG, Van der Pol WL, Goedee HS, Steenhuis M, Keijzer S, Keijser JBD, Boogaard A, Cristianawati O, Ten Brinke A, Verstegen NJM, Zwinderman KAH, Rispens T, van Ham SM, Kuijpers TW, Eftimov F; T2B! immunity against SARS-CoV-2 study group. Stalman EW, et al. Ann Rheum Dis. 2022 Dec;81(12):1757-1766. doi: 10.1136/ard-2022-222904. Epub 2022 Sep 5. Ann Rheum Dis. 2022. PMID: 36357161
Impact of COVID-19 disease and vaccination on dermatological immune-mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo: a Target2B! substudy.
van Buchem-Post NF, Ouwerkerk W, Stalman EW, van Dam KPJ, Wieske L, Bekkenk MW, Wolkerstorfer A, Spuls P, Musters AH, Bosma AL, Hijnen DJ, Eftimov F, Luiten RM; T2B! immunity against SARS‐CoV‐2 study group; van Kempen ZLE, Stalman EW, Steenhuis M, Kummer LYL, van Dam KPJ, Ten Brinke A, van Ham SM, Kuijpers T, Rispens T, Eftimov F, Wieske L, Killestein J, Kooi AJV, Raaphorst J, Zwinderman AHK, Löwenberg M, Volkers AG, D'Haens GRAM, Takkenberg RB, Tas SW, Hilhorst ML, Vegting Y, Bemelman FJ, Verstegen NJM, Fernandez L, Keijzer S, Keijser JBD, Cristianawati O, Voskuyl AE, Broens B, Sanchez AP, Nejentsev S, Mirfazeli ES, Wolbink GJ, Boekel L, Rutgers BA, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart R, Teng Y, Busch MH, Brusse E, van Doorn PA, Baars M, Schreurs C, van der Pol WL, Goedee HS, van Els CACM, de Wit J. van Buchem-Post NF, et al. J Dermatol. 2025 Apr;52(4):624-633. doi: 10.1111/1346-8138.17664. Epub 2025 Feb 14. J Dermatol. 2025. PMID: 39950702 Free PMC article.
Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases.
Wieske L, Stalman EW, van Dam PJK, Kummer LY, Steenhuis M, van Kempen ZLE, Killestein J, Volkers AG, Tas SW, Boekel L, Wolbink G, Van der Kooi A, Raaphorst J, Löwenberg M, Takkenberg B, D'Haens GRAM, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Hilhorst ML, Vegting Y, Bemelman FJ, Voskuyl A, Broens B, Parra Sanchez A, van Els CACM, Wit J, Rutgers A, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart CF, Teng YKO, van Paassen P, Busch MH, Jallah PBP, Brusse E, van Doorn PA, Baars AE, Hijnen D, Schreurs CRG, Van der Pol WL, Goedee HS, Keijzer S, Keijser J, Cristianawati O, Ten Brinke A, Verstegen NJM, Zwinderman KAH, van Ham SM, Kuijpers TW, Rispens T, Eftimov F; T2B! immunity against SARS-CoV-2 study group. Wieske L, et al. Ann Rheum Dis. 2023 Jun;82(6):883-885. doi: 10.1136/ard-2022-223464. Epub 2023 Jan 31. Ann Rheum Dis. 2023. PMID: 36720583 No abstract available.
Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccination.
Valk AM, Keijser JBD, van Dam KPJ, Stalman EW, Wieske L, Steenhuis M, Kummer LYL, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Horváth B, Hijnen DJ, Schreurs CRG, van Kempen ZLE, Killestein J, Volkers AG, Tas SW, Boekel L, Wolbink GJ, Keijzer S, Derksen NIL, van Deelen M, van Mierlo G, Kuijpers TW, Eftimov F, van Ham SM, Ten Brinke A, Rispens T; T2B! Immunity against SARS‐CoV‐2 study group. Valk AM, et al. Allergy. 2024 Jul;79(7):1952-1961. doi: 10.1111/all.16089. Epub 2024 Mar 4. Allergy. 2024. PMID: 38439527
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases.
Wieske L, Kummer LYL, van Dam KPJ, Stalman EW, van der Kooi AJ, Raaphorst J, Löwenberg M, Takkenberg RB, Volkers AG, D'Haens GRAM, Tas SW, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Hilhorst ML, Vegting Y, Bemelman FJ, Killestein J, van Kempen ZLE, Voskuyl AE, Broens B, Sanchez AP, Wolbink G, Boekel L, Rutgers A, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart CF, Teng YKO, van Paassen P, Busch MH, Jallah BP, Brusse E, van Doorn PA, Baars AE, Hijnen D, Schreurs CRG, van der Pol WL, Goedee HS, Steenhuis M, Rispens T, Ten Brinke A, Verstegen NJM, Zwinderman KAH, van Ham SM, Kuijpers TW, Eftimov F; T2B! immunity against SARS-CoV-2 study group. Wieske L, et al. BMC Med. 2022 Mar 2;20(1):100. doi: 10.1186/s12916-022-02310-7. BMC Med. 2022. PMID: 35236350 Free PMC article.
25 results